“You shouldn’t have to fight your cancer and your insurance company’s co-payments."

NPLB noted that including factors, such as diminishing returns and dynamic pricing, helps assess medication value better than traditional CEA.

Rubin speaks about how drugs aren’t being properly valued.

No Patient Left Behind’s updated methodology accounts for disease severity, loss of market exclusivity and social value

Biopharma CEOs, investors call for same timeline for biologics, small molecules and lower out-of-pocket costs